(Table 4 and S3 Table) It indicated that the immune level of SCLC was relatively low, and application of IL-6 inhibitors, immunotherapy or activation of immunity might be the potential strategies for the treatment of SCLC. This evidence concerns the gene IL6 and small cell lung carcinoma.